Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of ascending doses of HepaStem in NASH with fibrosis and cirrhosis
2018-004449-18Phase 2Completed
- Sponsor
- Promethera Therapeutics
- Start
- Dec 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hepastem in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD) and Cirrhosis, sponsored by Promethera Therapeutics. Primary endpoint: Primary safety and dose-finding endpoint. Started Dec 2018; status: completed.
02
Drugs
hepastem
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)Cirrhosis
Beyond the preview
Go deeper on 2018-004449-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004449-18.